Heterocyclic Compounds for CNS Disorders via Multi-Target Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic drugs for treating central nervous system diseases, such as depression and schizophrenia, have limitations including slow onset of action, poor efficacy, and side effects like extrapyramidal reactions and metabolic disorders, necessitating the development of new compounds with improved efficacy and reduced side effects.
Innovation Solution
A novel class of heterocyclic compounds with serotonin 2A (5-HT2A) receptor antagonism and/or dopamine D2 and serotonin 1A (5-HT1A) receptor activities, represented by a specific general formula, are developed for treating central nervous system disorders, including depression, schizophrenia, and anxiety, with a focus on multi-target receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional antipsychotics are used, then they can treat central nervous system diseases, but they have slow onset of action and poor efficacy
Solution Approach 1:
The compound combines multiple pharmacological activities (5-HT1A agonism, 5-HT2A antagonism, D2 partial agonism) into a single molecule, enabling simultaneous modulation of multiple neurotransmitter systems. This multi-target approach accelerates onset of action and improves efficacy by addressing multiple pathological mechanisms of CNS disorders concurrently
Solution Approach 2:
The heterocyclic compound serves multiple functions: it acts as a 5-HT1A receptor agonist, 5-HT2A receptor antagonist, and D2 receptor partial agonist. This multi-functionality allows a single drug to treat various symptoms of CNS disorders including depression, anxiety, and psychosis with improved speed and efficacy
2Reliability
If D2 receptor antagonists are used, then they can treat schizophrenia and insomnia, but they cause side effects such as extrapyramidal reactions
Solution Approach 1:
The compound merges D2 partial agonism with 5-HT1A agonism and 5-HT2A antagonism. The 5-HT1A agonist activity counteracts the extrapyramidal side effects of D2 antagonism, while the 5-HT2A antagonism enhances antipsychotic efficacy. This combination maintains treatment effectiveness while reducing harmful side effects
Solution Approach 2:
The compound changes the pharmacological parameter from pure D2 antagonism to D2 partial agonism, which provides sufficient antipsychotic effect while reducing the risk of extrapyramidal reactions. Simultaneous 5-HT1A agonism further modulates the dopaminergic system to minimize side effects
3Reliability
If D2/5-HT2A receptor antagonists are used, then they can improve negative symptoms and cognitive impairment, but they cause metabolic disorders and weight gain
Solution Approach 1:
The compound combines 5-HT1A agonism with 5-HT2A antagonism and D2 partial agonism. The 5-HT1A agonist activity is associated with improved metabolic profile compared to pure 5-HT2A antagonists, while maintaining the beneficial effects on negative symptoms and cognitive impairment. This multi-target approach achieves therapeutic goals with reduced metabolic side effects
4Reliability
If multiple receptor activities are combined, then efficacy is improved, but drug complexity increases
Solution Approach 1:
Multiple pharmacological activities (5-HT1A agonism, 5-HT2A antagonism, D2 partial agonism) are merged into a single heterocyclic compound molecule. This molecular design achieves broad therapeutic efficacy against various CNS disorders while maintaining a unified drug structure, simplifying the treatment regimen despite the complexity of multi-target modulation
Data Source
AI summary
Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and/or treatment of a central nervous system disease.